The ability to introduce manipulated genes and delete or modify endogenous genes in the germline of animals is a major technological advance in biology, enabling investigators to answer questions about gene function which must be analyzed in a whole animal model system. Transgenic and knockout animals have been instrumental in providing insights into mechanisms of developmental gene regulation, cellular interactions within the immune system, and the effect of oncogenes on growth and differentiation. Demand for these services has remained high during the current review period. In 2009, 67 requests were completed, and ninety-four percent (94%) of Facility usage was by peer-reviewed, funded investigators for this service. In addition, the Facility's cryopreservation service is highly utilized, resulting in freezing of 106 lines during the period 2005-2009, providing important insurance against the loss of irreplaceable mouse lines in the event of a catastrophic event in the Transgenic Mouse Facility (TMF). Over the past five years all five of the CCSG Programs have used the Facility. The Facility has recently added and validated the capacity to carry out Zinc finger nuclease (ZFN)-mediated gene targeting, a methodology that considerably accelerates and simplifies the generation of knockout and knock-in mice, and allows generation of complex mouse models with multiple genetic alterations that were not previously feasible. Kappes (Immune Cell Development and Host Defense (ICDHD) Program), has directed this resource since 1995 and has responsibility for Facility operations. Equitable access to the Facility is assured by Facility policy, oversight from a user facility advisory committee and a governing Facilities Parent Oversight Committee (FPOC).

Public Health Relevance

Transgenic and knockout animals have been instrumental in providing insights into mechanisms of developmental gene regulation, cellular interactions within the immune system, and the effect of oncogenes on growth and differentiation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
7P30CA006927-50
Application #
8475335
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
50
Fiscal Year
2013
Total Cost
$50,752
Indirect Cost
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Fareed, Muhammad M; Eldib, Ahmed; Weiss, Stephanie E et al. (2018) A treatment planning comparison between a novel rotating gamma system and robotic linear accelerator based intracranial stereotactic radiosurgery/radiotherapy. Phys Med Biol 63:035029
Bleicher, Richard J (2018) Timing and Delays in Breast Cancer Evaluation and Treatment. Ann Surg Oncol 25:2829-2838
Bai, Tian; Chanda, Ashis Kumar; Egleston, Brian L et al. (2018) EHR phenotyping via jointly embedding medical concepts and words into a unified vector space. BMC Med Inform Decis Mak 18:123
Mehrazin, Reza; Dulaimi, Essel; Uzzo, Robert G et al. (2018) The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma. Ther Adv Urol 10:3-10
Tang, Baiqing; Lee, Hyung-Ok; An, Serim S et al. (2018) Specific Targeting of MTAP-Deleted Tumors with a Combination of 2'-Fluoroadenine and 5'-Methylthioadenosine. Cancer Res 78:4386-4395
Fang, Carolyn Y; Tseng, Marilyn (2018) Ethnic density and cancer: A review of the evidence. Cancer 124:1877-1903
Malik, R; Luong, T; Cao, X et al. (2018) Rigidity controls human desmoplastic matrix anisotropy to enable pancreatic cancer cell spread via extracellular signal-regulated kinase 2. Matrix Biol :
Giri, Veda N; Obeid, Elias; Hegarty, Sarah E et al. (2018) Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling. Prostate 78:879-888
Anari, Fern; O'Neill, John; Choi, Woonyoung et al. (2018) Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. Eur Urol Oncol 1:54-60
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739

Showing the most recent 10 out of 1280 publications